Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression
In the study, published on
“These findings demonstrate why we’re able to generate sustained immune system activation, and also why measuring the level of immunogenicity at a single point in time is often not predictive of anti-cancer activity,” said
One of the key findings of the study is the fundamentally unique method by which Immunovaccine’s technology delivers immune-activating agents, such as cancer peptides, to the immune system. Unlike other technologies that rely on a slow release of antigens at the site of injection, Immunovaccine’s delivery formulation entraps the immuno-stimulating agents at the injection site. This ‘depot’ effect forces an active uptake by immune cells, rather than a passive diffusion at the injection site. Hence, the immune-stimulating components are protected from degradation, are delivered over a prolonged period of time to antigen-presenting cells, and are actively transported to the lymph nodes.
“In this publication, we have shown that enhanced tumor control can be correlated with our unique MOA in tumor models, which provides insight as to why our technology may be able to provide anti-cancer responses that have not yet been associated with other approaches,” said Frederic Ors, Immunovaccine’s Chief Executive Officer. “Effective T cell responses have been linked to clinical benefits of successful cancer immunotherapies. We believe that by generating a prolonged in vivo T cell targeted attacks on cancer cells, our technology represents a promising alternative to ex vivo programming of T cells, such as those associated with CAR T therapies.”
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals.
T: (312) 961-2502 E: email@example.com
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: firstname.lastname@example.org
O: (415) 513-1284
T: (415) 515-4572 E: email@example.com
i Published online,
Source: Immunovaccine Inc.